Video

Dr. Grignani on the Patient Population of Trabectedin for Sarcoma

Author(s):

Giovanni Grignani, MD

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.

This is a new option that oncologists should consider for frail patients who have soft tissue sarcoma.

Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
John Mascarenhas, MD
Related Content
R. Lor Randall, MD, FACS
December 5th 2024

Preclinical Data Highlight YAP1 and KRAS as Drivers in Soft Tissue Sarcomas

Gina Z. D’Amato, MD
February 9th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

2rogan – stock.adobe.com
November 12th 2024

Elraglusib Earns FDA Rare Pediatric Disease Designation for Ewing Sarcoma

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors
December 29th 2022

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

Fixed-Dose CAR T Cells and UB-TT170 in R/R Osteosarcoma | Image Credit: © MdBabul - stock.adobe.com
November 11th 2024

Fixed-Dose CAR T Cells Followed by Escalating UB-TT170 Increases Cytokine Levels in R/R Osteosarcoma

Here is your snapshot of all therapeutic options that the FDA approved in October 2024.
November 5th 2024

OncLive’s October Roundup of Key FDA Approvals in Oncology